1. How many patients with cutaneous squamous cell carcinoma have you treated?
2. How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated?
3. Of these how many are not candidates for curative surgery or curative radiation?
4. In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
Libtayo (cemiplimab)
Non curative surgery only
Non curative surgery + chemotherapy*
Non curative surgery + radiotherapy
Non curative surgery + chemotherapy* + radiotherapy
Chemotherapy* only
Chemotherapy* + radiotherapy
Non curative radiotherapy only
No treatment
Palliative Care / Best Supportive care
Other [please state]
*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide
5. Does your trust treat adult multiple myeloma [MM]? – if you refer your multiple myeloma patients to another centre, please state which.
6. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
Bortezomib [Velcade]
Carfilzomib [Kyprolis]
Ixazomib [Ninlaro]
Lenalidomide [Revlimid]
Daratumumab [Darzalex]
Melphalan, prednisolone and thalidomide (known as MPT)
Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
Pomalidomide [Imnovid]
7. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible how many CLL patients treated were new to therapy in the past 3 months?
8 How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
Bendamustine and rituximab (known as BR)
Ibrutinib [Imbruvica]
Chlorambucil
Venetoclax
Obinutuzumab
Idelalisib
Fludarabine and rituximab (known as FR)
High-dose prednisone and rituximab
Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
Alemtuzumab (Campath) with rituximab
